


REMARKS/ARGUMENTS

As referred to in Applicants response, attached hereto is a Declaration from Mr. Onuma providing experimental results demonstrating that anti-PTHrP antibody when administration resulted in an increase in vasopressin. However, if administered Alendronate (sodium [4-amino-1-hydroxy-1-(hydroxy-oxido-phosphoryl)- butyl]phosphonic acid trihydrate), this did not effect vasopressin levels in the blood. Alendronate is a typical therapeutic agent for treating humoral hypercalcemia of malignancy (HHM) thus indicting that therapeutic effects on HHM bears no immediate relationship to vasopressin in the blood.

Reconsideration of the outstanding rejections in light of the amendments and remarks contained previously submitted and the attached Declaration is requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Daniel J. Pereira
Registration No. 45,518

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/07)